lomustine
lomustine: 10 clinical trials tracked.
lomustine evidence translation
What we can confirm
10 tracked trials
What it means
What to watch
Prepared research question
What is verified about lomustine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 5 study sponsors
Related indications
Clinical Trials (10)
Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients With Recurrent Glioblastoma
Primary endpoint: Overall survival (OS)
A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features
Primary endpoint: Percentage of patients with >= grade 2 hearing loss
Tofacitinib: Suppressing Tumor Invasion in Recurrent GBM Patients
Primary endpoint: Progression-free Survival (PFS) of the Study Cohort as Defined by RANO Criteria.
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
Primary endpoint: Overall survival
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Primary endpoint: Overall Survival
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Primary endpoint: Overall Survival (OS)
Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors
Primary endpoint: Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 With Subsequent Extension of Optimal Dose in Recurrent GBM Subjects
Primary endpoint: Dose limiting toxicity (DLT) occurring during Part A of the study
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Primary endpoint: Progression-free survival (PFS)
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
Primary endpoint: Event-free Survival (EFS)